We hereby inform you that the Board of Directors of the Company at its meeting held today has approved the Unaudited Standalone financial results of the Company for the quarter and half ....

Net loss reportedNegative operating cash flowExceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.9%Reaction day

₹12.78

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.8% vs market

Pharmaceuticals peers, median of 157sector-0.0%-4.9% vs sector

On the reaction day the stock moved 4.8 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.9-0.1-4.8-0.0-4.9

Next day

-8.5-0.2-8.3-0.4-8.0

-12.8+0.4-13.2-0.3-12.4

-17.1-0.4-16.7-1.0-16.0

-21.0-0.6-20.4-1.3-19.7

-24.4-0.9-23.5-1.5-22.9

—-3.0—-3.3—

15d

—-3.9—-3.4—

-37.6-4.8-32.7-4.0-33.5

-16.7-7.8-8.9-6.6-10.0

—-7.2—-8.7—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Adline Chem Lab's board approved unaudited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025). The company reported a loss of Rs 7.26 lakhs for Q2 FY26 and Rs 12.21 lakhs for H1 FY26, an improvement from the Rs 21.90 lakh loss in H1 FY25, but it continues to post losses. Revenue from operations appears negligible with most income classified as 'other income' (Rs 24.99 lakhs for the quarter). The company's other equity is deeply negative at Rs (746.41) lakhs, and it is relying on borrowings (Rs 164.95 lakhs, up from Rs 148.78 lakhs) to fund operations, with negative operating cash flow of Rs (9.50) lakhs in H1 FY26. Two key directors — Managing Director Sarang Pathak and Non-Executive Promoter Director Hemant Parikh — resigned with effect from close of business on November 12, 2025. Vrushank Patel, an existing Executive Director, has been appointed as the new Chairman to ensure leadership continuity.

Likely market impact

Sharp negative for shareholders — the company is loss-making with severely eroded net worth (negative reserves of Rs 746+ lakhs against equity capital of Rs 585 lakhs), suggesting possible going-concern risks despite reduced quarterly losses. The sudden exit of the Managing Director and a Promoter Director raises governance red flags, though continuity has been maintained by elevating an existing director as Chairman. Investors should treat this as a high-risk, micro-cap situation.